Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Key Inclusion Criteria:

• Participated in a prior dupilumab study in pediatric participants with AD andadequately completed the visits and assessments required for both the treatment andfollow-up periods, as defined in the prior study protocol

• PFP Sub-Study Only:

• Age ≥2 to <12 years at time of screening

• Body weight ≥5 kg and <60 kg at time of screening

• Must have received the same dupilumab dose regimen to be used in the PFP sub-studyduring the previous 12 weeks in the main OLE study using the prefilled syringe, asdefined in the protocol

Key Exclusion Criteria:

• Participants who, during their participation in a prior dupilumab study developed anadverse event (AE) or serious adverse event (SAE) deemed related to study drug whichcould indicate that continued treatment with study drug may present an unreasonablerisk for the patient

• Participants, who during the participation in a prior Dupilumab study, developed anAE that was deemed related to study drug and led to study treatment discontinuation,which in the opinion of the investigator or medical monitor could indicate thatcontinued treatment with study drug may present an unreasonable risk for the patient

• Treatment with an investigational drug, other than dupilumab, within 8 weeks orwithin 5 half-lives (if known), whichever is longer, before the baseline visit

• Having used immunosuppressive/immunomodulating drugs within 4 weeks before thebaseline visit

• Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit

• Diagnosed active endoparasitic infections or at high risk of these infections

• Severe concomitant illness(es) that, in the investigator's judgment, would adverselyaffect the participant's participation in the study

• PFP Sub-study Only:

• Poor compliance as defined by having missed 1 or more of the planned last 3injections in the main OLE study prior to entering the sub-study

• Switched dupilumab doses within the past 12 weeks

• Meet criteria for temporary/permanent discontinuation of study drug at time ofscreening into PFP sub-study, as defined in the protocol.

Note: Other protocol defined Inclusion / Exclusion criteria may apply